Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Compound Realgar-Indigo Naturalis Plus Irinotecan in Late-Stage Gastric Cancer
ChiCTR-INR-16009947Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) comparing Compound Realgar-Indigo Naturalis Tablet + irinotecan with Placebo + irinotecan (2 arms). Primary endpoint: progression-free survival. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
Compound Huangdai Tablet
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-INR-16009947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-INR-16009947.